Tekin Burak, Folpe Andrew L, Dasari Surendra, Hofich Christopher D, McCarthy Michael, Alvand Saba, Pujari Ganesh P, Halling Kevin C, Cheville John C, Whaley Rumeal D, Gupta Sounak
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Hum Pathol. 2025 Mar;157:105768. doi: 10.1016/j.humpath.2025.105768. Epub 2025 Apr 4.
Glycoprotein non-metastatic melanoma protein B (GPNMB) is a transcriptional target of MiTF/TFE3. Prior studies have shown that immunohistochemistry for GPNMB is a sensitive screening tool for renal cell carcinomas with alterations of TSC1/TSC2/MTOR, TFE3, and TFEB genes, as well as alveolar soft part sarcomas (ASPS) and perivascular epithelioid cell neoplasms (PEComas). However, GPNMB expression has not been systematically evaluated in a diverse group of molecularly confirmed, TFE3-rearranged mesenchymal tumors.
Our archive was interrogated for TFE3-rearranged non-renal neoplasms previously assessed with our RNA NGS panel. For each case, a whole-slide section was immunostained for GPNMB, and quantified using H-scores. The methylation profiles of the included tumor types were retrieved from our database.
Thirteen TFE3-rearranged tumors were identified, including 6 ossifying fibromyxoid tumors (OFMTs) (PHF1::TFE3), 3 PEComas/PEComa-like neoplasms (ASPSCR1::TFE3, DVL2::TFE3, and PRCC::TFE3, one case each), 2 YAP1::TFE3-rearranged hemangioendotheliomas, one ASPS (ASPSCR1::TFE3), and one unclassified CBX4::TFE3-rearranged sarcoma. Tumors harboring ASPSCR1, PRCC, YAP1, and DVL2 as the fusion partner had a mean H-score of 300, 300, 290 and 280, respectively. All 6 PHF1::TFE3-rearranged OFMTs and the CBX4::TFE3-rearranged sarcoma were GPNMB-negative, despite having similar TFE3 breakpoints to the positive cases (exon 6-7). PHF1::TFE3-rearranged OFMT showed relative hypermethylation of the GPNMB promoter locus cg02203656 compared to ASPS (p = 0.027).
Although study of additional cases is necessary, these findings suggest that the downstream effects of TFE3-rearrangement are different in PHF1::TFE3-rearranged OFMTs, compared to other known TFE3-rearranged neoplasms. TFE3-rearranged OFMTs are epigenetically distinct, implying that the impact of TFE3-rearrangement may be lineage-dependent.
糖蛋白非转移性黑色素瘤蛋白B(GPNMB)是MiTF/TFE3的转录靶点。先前的研究表明,GPNMB免疫组化是一种敏感的筛查工具,可用于检测伴有TSC1/TSC2/MTOR、TFE3和TFEB基因改变的肾细胞癌,以及肺泡软组织肉瘤(ASPS)和血管周上皮样细胞瘤(PEComas)。然而,尚未在一组经分子确认的、TFE3重排的间质性肿瘤中系统评估GPNMB的表达情况。
我们查询了存档中先前用我们的RNA二代测序(NGS)检测板评估过的TFE3重排的非肾肿瘤。对每例病例,进行GPNMB全玻片免疫染色,并使用H评分进行定量。从我们的数据库中检索所纳入肿瘤类型的甲基化谱。
共鉴定出13例TFE3重排肿瘤,包括6例骨化性纤维黏液样肿瘤(OFMTs)(PHF1::TFE3)、3例PEComas/PEComa样肿瘤(ASPSCR1::TFE3、DVL2::TFE3和PRCC::TFE3,各1例)、2例YAP1::TFE3重排的血管内皮瘤、1例ASPS(ASPSCR1::TFE3)和1例未分类的CBX4::TFE3重排肉瘤。以ASPSCR1、PRCC、YAP1和DVL2作为融合伴侣的肿瘤,其平均H评分分别为300、300、290和280。所有6例PHF1::TFE3重排的OFMTs和CBX4::TFE3重排的肉瘤均为GPNMB阴性,尽管它们与阳性病例的TFE3断点相似(外显子6-7)。与ASPS相比,PHF1::TFE3重排的OFMT显示GPNMB启动子位点cg02203656相对高甲基化(p = 0.027)。
尽管需要研究更多病例,但这些发现表明,与其他已知的TFE3重排肿瘤相比,PHF1::TFE3重排的OFMTs中TFE3重排的下游效应有所不同。TFE3重排的OFMTs在表观遗传学上是不同的,这意味着TFE3重排的影响可能具有谱系依赖性。